Difference between revisions of "Cabozantinib (Cometriq)"
Jump to navigation
Jump to search
m (→References) |
m |
||
| Line 8: | Line 8: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Prostate cancer]] | *[[Prostate cancer]] | ||
| + | *[[Renal cancer]] | ||
*[[Thyroid_cancer#Medullary_thyroid_cancer | Medullary thyroid cancer]] | *[[Thyroid_cancer#Medullary_thyroid_cancer | Medullary thyroid cancer]] | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
==Patient drug information== | ==Patient drug information== | ||
| Line 29: | Line 18: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*11/29/2012: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm330213.htm FDA approved] for treatment of "progressive metastatic [[Thyroid_cancer#Medullary_thyroid_cancer | medullary thyroid cancer (MTC)]]" | *11/29/2012: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm330213.htm FDA approved] for treatment of "progressive metastatic [[Thyroid_cancer#Medullary_thyroid_cancer | medullary thyroid cancer (MTC)]]" | ||
| + | *4/25/2016: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm497483.htm FDA approved] for the treatment of [[Renal_cancer|advanced renal cell carcinoma]] in patients who have received prior [[:Category:VEGF_inhibitors|anti-angiogenic therapy]]. | ||
==Also known as== | ==Also known as== | ||
| Line 50: | Line 40: | ||
[[Category:VEGF inhibitors]] | [[Category:VEGF inhibitors]] | ||
[[Category:Prostate cancer medications]] | [[Category:Prostate cancer medications]] | ||
| + | [[Category:Renal cancer medications]] | ||
[[Category:Thyroid cancer medications]] | [[Category:Thyroid cancer medications]] | ||
[[Category:Drugs FDA approved in 2012]] | [[Category:Drugs FDA approved in 2012]] | ||
Revision as of 01:52, 26 April 2016
General information
Class/mechanism: Tyrosine kinase inhibitor; inhibits RET, MET/c-Met, VEGFR-1, VEGFR-2, VEGFR-3, KIT, TRKB, FLT-3, AXL, and TIE-2.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Cabozantinib (Cometriq) package insert pages 20-24[1] (the numbering for the PDF is off, so in some PDF viewers, the patient information is on pages 27-31)
- Cabozantinib (Cometriq) patient drug information (Chemocare)[4]
- Cabozantinib (Cometriq) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 11/29/2012: FDA approved for treatment of "progressive metastatic medullary thyroid cancer (MTC)"
- 4/25/2016: FDA approved for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy.
Also known as
XL184 or XL-184.